Protocol I1F- MC-RHCU(b)  
 
Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation 
in Healthy  Subjects  
 
[STUDY_ID_REMOVED] 
 
Approval Date: 29- Sep-2020 
 
 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 1
LY2439821Protocol I1F-MC-RHCU (b)
Bioequivalence of an Alternat eIxekizumab F ormulation
Compared to the Commercial Formulation in Healthy  
Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
ixekizumab (LY2439821 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercial ly confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries .  
Ixekizumab (LY2439821)
Eli Lilly and Company
Indianapolis, Indiana ,USA 46285
Clinical Pharmacology Protocol Approved by Lilly:13November 2019 .
Amendm ent (a) Electronically Signed and Approved by Lilly:  21February 2020
Amendm ent (b) Electronically Signed and Approved by Lilly
onapproval date provided below.
Approval Date: 29-Sep-2020 GMT
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 2
LY2439821Table of Contents
Bioequivalence of an Alternat e Ixekizumab Formulation
Compared to the Commercial Formulation in Healthy  
Subjects
Section Page
Protocol  I1F-MC-RHCU(b) Bioequivalence of an Alternate Ixekizumab 
Form ulation Co mpared to the Commercia l Form ulation in Healt hy 
Subjects .............................................................................................................................. 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 7
2. Schedule of Act ivities....................................................................................................... 10
3. Intro duction ...................................................................................................................... 14
3.1. Study  Rati onale ............................................................................................................ 14
3.2. Background .................................................................................................................. 14
3.3. Benefit/Risk Assessment .............................................................................................. 14
4. Object ives and Endpo ints.................................................................................................. 17
5. Study  Design ..................................................................................................................... 18
5.1. Overall Design ............................................................................................................. 18
5.2. Number of Participants .................................................................................................19
5.3. End of Study  Definit ion............................................................................................... 19
5.4. Scientific Rationale for Study  Design ........................................................................... 19
5.5. Justification for Dose ................................................................................................... 20
6. Study  Popul ation............................................................................................................... 21
6.1. Inclusio n Cri teria.......................................................................................................... 21
6.2. Exclu sion Criteria........................................................................................................ 23
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 26
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 26
6.3.1. Meals and Dietary  Restri ctions............................................................................. 26
6.3.2. Alcoho l and Tobacco ........................................................................................... 26
6.3.3. Activity................................................................................................................ 27
6.4. Screen Failures ............................................................................................................. 27
7. Treatment .......................................................................................................................... 28
7.1. Treatment Administered ............................................................................................... 28
7.1.1. Packaging and Labeling ....................................................................................... 28
7.2. Method of Treatment Assignment ................................................................................ 29
7.2.1. Selection and Timing o f Doses ............................................................................. 29
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 3
LY24398217.3. Blinding ....................................................................................................................... 29
7.4. Dose Modificat ion........................................................................................................ 29
7.4.1. Speci al Treatm ent Consi derat ions........................................................................ 29
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 30
7.6. Treatment Compliance .................................................................................................30
7.7. Concomitant Therapy ................................................................................................... 30
7.8. Treatment after the End of the Study ............................................................................ 31
8. Discontinuati on Cri teria .................................................................................................... 32
8.1. Discontinuation fro m Study  Treatm ent......................................................................... 32
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 32
8.2. Discontinuati on from the Study .................................................................................... 32
8.3. Subjects Lost to Follow -up........................................................................................... 32
9. Study  Assessments and Procedures ................................................................................... 33
9.1. Efficacy Assessments ................................................................................................... 33
9.2. Adverse Events ............................................................................................................ 33
9.2.1. SeriousAdverse Events ........................................................................................ 34
9.2.1.1. Adverse Events of Special Interest .................................................................. 34
9.2.1.2. Suspected Unexpected Serious Adverse React ions.......................................... 35
9.2.1.3. Systemic Hypersensit ivity Reactions .............................................................. 36
9.2.2. Com plaint Handling ............................................................................................. 36
9.3. Treatment of Overdose .................................................................................................36
9.4. Safety........................................................................................................................... 36
9.4.1. Laboratory  Test s.................................................................................................. 37
9.4.2. Vital Signs ........................................................................................................... 37
9.4.3. Electrocardiograms .............................................................................................. 37
9.4.4. Temperature ......................................................................................................... 37
9.4.5. Other T ests........................................................................................................... 37
9.4.5.1. Inject ion Site Assessments .............................................................................. 37
9.4.5.2. Bleeding/Bruising Assessment ........................................................................ 38
9.4.5.3. Columbia Suici de Severi ty Rating Scal e......................................................... 38
9.4.5.3.1. Hospital Anxiet y Depressio n Scale ........................................................... 38
9.4.6. Safety Moni toring ................................................................................................ 39
9.4.6.1. Hepati c Safet y................................................................................................ 39
9.5. Pharmacokinet ics......................................................................................................... 39
9.5.1. Bioanalysis ........................................................................................................... 39
9.6. Pharmacodynamics ...................................................................................................... 40
9.6.1. Immunogenici ty Assessments .............................................................................. 40
9.7. Genet ics....................................................................................................................... 40
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 4
LY24398219.8. Biomarkers ................................................................................................................... 41
9.9. Heal th Econom ics........................................................................................................ 41
10. Statistical Considerations and Data Analysis ..................................................................... 42
10.1. Sample Si ze Determinat ion.......................................................................................... 42
10.2. Popul ations for Analyses .............................................................................................. 42
10.2.1. Study  Parti cipant Disposit ion............................................................................... 42
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 42
10.3. Statistical Analyses ...................................................................................................... 42
10.3.1 .Safety Analyses .................................................................................................... 43
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 43
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 43
10.3.1.2.1. Statistical Evaluat ion of Other Safet y Param eters ...................................... 43
10.3.2. Pharmacokinet ic Analyses .................................................................................... 43
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 43
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 43
10.3.3. Evaluat ion of Immunogenicit y............................................................................. 44
10.3.4. Interim Analyses .................................................................................................. 44
11. References ........................................................................................................................ 45
12. Appendices ....................................................................................................................... 46
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 5
LY2439821List of Tables
Table Page
Table RHCU.1. Object ives and Endpo ints....................................................................... 17
Table RHCU.2. Study  RHCU Stratificat ion and Rando mizat ion Plan .............................. 18
Table RHCU.3. Treatments Administered ........................................................................ 28
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 6
LY2439821List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 47
Append ix 2. Clinical Laboratory  Tests ........................................................................ 52
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 53
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 56
Appendix 5. Blood Sam pling Summary ...................................................................... 57
Appendix 6. Reco mmended Laboratory Test ing for Hypersensit ivity Events.............. 58
Appendix 7. Protocol  Amendment I1F -MC-RHCU(b) Summary Bioequivalence 
of an Al ternate Ixeki zumab Form ulation Co mpared to the 
Commercial Formulat ion in Healt hy Subjects ......................................... 59
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 7
LY24398211.Protocol Synopsis
Title of Study:
Bioequiva lence of an Alternate Ixekizumab Formulat ion Co mpared to the Commercial 
Form ulation in Healthy Subjects
Rationale :  
Two studies (I1F -MC-RHCS [RHCS] and I1F -MC-RHCT [RHCT]) in healt hy vo lunteers have 
been conducted for the purpose of select ing an alternat ive formulation to the currently marketed 
formulation.  Study  RHCS was conducted to investigate injection site pain fo llowing 
subcutaneous ( SC)inject ions of 2 ixekizumab alternate formulat ions co mpared to the 
ixekizumab co mmercial formulat ion using a prefilled s yringe ( PFS).  Study  RHCT was 
conducted to compare the relat ive bioavailabilit y, safety, and tolerabilit y of 2 alternate 
formulations of ixekizumab to the commercial product when administered subcutaneously via 
PFS.  The active ingredient concentration and the inject ion volume o f the alternate formulat ions 
were the sam e as the commercial drug product.  
Based on the results of Studies RHCS and RHCT, a formulat ion was selected to take forward 
into the present Study  I1F-MC-RHCU (RHCU) which is being conducted to evaluate the 
bioequivalence of the selected ixekizumab alternate formulat ion (test), compared to the 
ixekizumab co mmercial formulat ion (reference) when administered using an autoinjector (AI).  
Objective(s)/Endpoints :  
Objectives Endpoints
Primary
To evaluate the bioequivalence of a single 80 mg SC 
dose of ixekizumab alternate formulation (test) 
compared to the ixekizumab commercial formulation 
(reference)Cmax, AUC(0 -∞), AUC(0 -tlast)
Secondary
To describe the safety and tolerability of a single 80 mg 
SC dose of ixekizumab alternate formulation (test) 
compared to the commercial formulation (reference)TEAEs, SAEs
Abbreviations:  AUC(0 -∞) = area under the concentration versus time curve from time zero to infinity; AUC(0 -tlast)= area under the 
concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration; C max= maximum 
observed drug concentration; SAE = serious adverse events; SC = subcutaneous; TEAE =treatment -emergent adverse event.
Summary of Study Design:   
Study  RHCU is a Phase 1, subject -blind, 2 -arm,rando mized, parallel -design study  in healt hy 
subjects.  
Eligible subjects will be admitted to the clinical research unit (CRU) on Day  -1and stratified into 
weight, f ormulation, and inject ion site categories as described in thetreatm ent arm s and planned 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 8
LY2439821durati onsection of this synopsis .  Subjects m ay be allowed to l eave the CR U after com pleting 
the 4-hour safet y assessments on Day  1, at the investigator’s discret ion, and will return for 
pharmacokinet ic (PK), immunogenicit y sampling, and safet y assessments at predefined times up 
to 12 weeks postdose.  Subjects will be mo nitored for safet y between outpatient visit s by way  of 
telephone assessment.
Safety and tol erabilit y will  be assessed by  clinical laboratory  tests, vi tal sign measurements, 
temperature, recording of adverse events ( AEs), physical  examinat ion (PE)/m edical  assessmen ts, 
Columbia Suici de Severi ty Rating Scal e (C-SSRS), and immunogenicit y.  
Treatment Arms and Planned Duration for an Individua l Subject :  
At screening, s ubjects will be stratified into 1 of 3 weight categories (<70.0 kg, 70.0 to 80.0 kg, 
>80.0 kg).  Within the 3 weight categories, subjects will be rando mized 1:1 to either 80- mg 
ixekizumab co mmercial formulat ion (reference) or 80 -mg ixekizumab alternate formulat ion 
(test) and subrando mized 1:1:1 to injection site (arm, thigh, or abdomen).  On Day  1, subjects 
will receive a single SC dose according to the randomizat ion plan.  Subjects will part icipate for 
up to 16weeks .
Number of Subjects :  
Up to approximately 240 subjects may be enrolled so that approximately 216 subjects complete 
the study  (108 in the 80- mg ixekizumab commercial formulat ion [reference] group and 108 in 
the 80-mg ixekizumab alternate formulat ion [test] group) .  
Statistical Analysis:
Pharmacokinet ic parameters will be evaluated to determine the bioequivalence of ixekizumab 
alternate form ulation (test) compared to the ixekizumab co mmercial formulat ion (reference).  
Log-transform ed maximum observed drug concentration (C max) and area under the 
concentration versus t ime curve ( AUC )param eters will be evaluated in a linear mixed -effects 
model with fixed effects for formulat ion and a random effect for subject.  The treatment 
differences wi ll be back -transform ed to present the ratios of geometric means and the 
corresponding 90% confidence interval ( CI).  Bioequivalence will be concluded if the 90% CI is 
completely contained within the interval (0.80, 1.25).
The time to m aximum  drug concentra tion (tmax) will be analyzed using a Wilcoxon rank sum 
test.  Estimates of the median difference based on the observed medians, 90% C Is,and p -values 
from the Wilcoxon rank sum test will be calculated.
Safety laboratory  param eters and vital signs data will be listed and summarized using standard 
descript ive statistics, where possible.  Suicidal ideation and/or behavior and self -injurious 
behavior with no suicidal intent, based on the C -SSRS, will be listed by subject.  Only subjects 
that show suicidal ideat ion/behavior or self -injuri ous behavior without suicidal intent will be 
included in the list ing (i .e., if a subject’s answers are all ‘no’ for the C -SSRS, then that subject 
will not be displayed).  Hospital Anxiet y Depression Scale ( HADS )item scores will be listed for 
subjects wi th HADS depressio n subscale ≥11 at any  time.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 9
LY2439821The frequency and percentage of subjects with preexist ing antidrug ant ibodies ( ADA s)and wi th 
treatm ent-emergent ADAs ( TE-ADA s)to ixekizumab will be tabulated.  Treatment -emergent 
ADAs are defined as those with a titer 2 -fold (1 dilution) greater than the minimum required 
dilution if no ADAs were detected at baseline (treatment -induced ADA s) or those wi th a 4-fold 
(2 dilut ions) increase in t iter compared to baseline if ADAs were detected at baseline (treatment -
boosted ADA s).  For the TE -ADA subjects, the distribut ion of maximum t iters will be described.  
The frequency of neutralizing ant ibodies will also be tabulated in TE -ADA sub jects.   
Addit ional analysis may  be perf ormed, if warranted, upon review o f the data.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 10
LY24398212.Schedule of A ctivities
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 11
LY2439821Study Schedule Protocol I1F -MC -RHCU
Screening Days Comments
Procedure-28 to -2 
days prior 
to Day 1-1 1 35
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±3d71
±3d85/ED
±3d
Informed Consent X
Medical History and 
DemographicsX
Review/Confirm 
Inclusion/Exclusion 
CriteriaX X
Subject Admission to 
CRUX
Subject Discharge 
from CRUXSubjects may be discharged 
after completion of the 4 -hour 
safety assessments on Day 1, at 
the investigator’s discretion.
Outpatient Visit X X X X X X X X X X X
Safety Assessment 
(Telepho ne Call)X X X
Randomization X
C-SSRS Lilly 
Self-Harm 
Supplement X X X X XAt screening ,‘Baseline -
Screening’ questionnaire to be 
used;all other time points use 
‘Since Last Visit’ questionnaire.
HADS Depression 
SubscaleX X X X X
Height , Weight, and 
BMIX XWeight only at Day 85/ED.
Body Temperature X P X X X X X X X X X X X
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 12
LY2439821Screening Days Comments
Procedure-28 to -2 
days prior 
to Day 1-1 1 35
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±3d71
±3d85/ED
±3d
Physical Examination 
/Medical Assessment
X XFull physical 
examination/medical 
assessment at Day -1 and at 
Day 85/E D.  Symptom -directed 
examinations/assessments may 
be conducted at other visits , as 
deemed necessary by the 
investigator.  
Vital Signs ( sitting )
(hours)
X XP, 
2-4XX X X XVital signs can be taken at any 
time during the 2 -to 4-hour 
window of Day  1.  Time points 
may be added if warranted and 
agreed upon between Lilly and
the investigator.
Clinical Lab oratory  
TestsX X X X XSeeAppendix 2 , Clinical 
Laborato ry Tests, for details.
SerologyXSeeAppendix 2 , Clinical 
Laborato ry Tests, for details.
QuantiFERON ®-TB 
Gold Test/TSTX
Ethanol Test and 
Urine Drug ScreenX XMay be repeated at the 
discretio n of the investigator.  
FSH Test
XFemales only, if applicable (see 
Section 6.1, criterion 1b see 
3ii).
Pregnancy Test 
X X XFemales only.  Serum 
pregnancy test will be 
performed at screening.  Urine 
pregnancy test will be 
performed at other indicated 
times .
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 13
LY2439821Screening Days Comments
Procedure-28 to -2 
days prior 
to Day 1-1 1 35
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±3d71
±3d85/ED
±3d
Single 12 -lead ECG X X
Ixekizumab
Administration XSubjects will fast (water is 
permitted ) from 1 hour before 
until 1 hour postdose .
Ixekizumab PK 
SampleP X X X X X X X X X X X
Immunogenicity 
Sample P X X XA time-matched PK should be 
taken at each immunogenicity 
sample time point.
Pharmacogenetic 
SampleP
AEs and Concomitant 
MedicationX X X X X X X X X X X X X X X X XIf an AEofISRis reported, the 
investigator ordesignee will 
complete a supplemental ISR 
AE form.
Abbreviations:  AE = adverse event; BMI = body mass index; CRU = clinical research unit; C-SSRS =Columbia Suicide Severity Rating Scale; d = days; ECG = 
electrocardiogram; ED =early discontinuation; FSH = follicle -stimulating hormone; HADS = Hospital Anxiety Depression Scale; ISR = injection site 
reaction; P = predose; PK =pharmacokinetics; TB = tuberculosis; TST =tuberculin skin test.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 14
LY24398213.Introduction
3.1. Study Rationale
Ixekizumab is a dministered subcutaneously and is available commercially as an injectable 
solution in eit her a m anual prefilled syringe ( PFS)or an autoinjector ( AI).  Each PFS or AI 
contains 80 mg ixekizumab in 1 mL.  Two studies ( I1F-MC-RHCS [ RHCS ]and I1F-MC-RHCT 
[RHCT ]) in healthy vo lunteers have been conducted for the purpose of selecting a n alternative 
formulation to the currently marketed form ulation.
Study  RHCS was conducted to invest igate inject ion site pain following subcutaneous ( SC)
inject ions of 2 ixekizumab alternate formulat ions com pared to the ixekizumab co mmercial 
formulation using a PFS .  Study  RHCT wasconducted to compare the relative bioavailabilit y, 
safet y, and tol erabili tyof2alternate formulations of ixekizumab to the commercial product
when administered subcutaneously via PFS .  The active ingredient concentration and the 
inject ion volumeof the al ternate formulat ionswere the sam e as the commercial drug product .
Based on the results of Studies RHCS and RHCT ,a form ulation was selected to take forward 
into the present Study  I1F-MC-RHC U(RHC U)which is being conducted to evaluate the 
bioequivalence ofthe selected ixekizumab alternate formulation(test) , com pared to the 
ixekizumab c ommercial formulation (reference) when administered using a n AI.  
3.2. Background
Ixekizumab (LY2439821, Taltz ®) is a humanized immunoglobulin G subclass 4 monoclonal 
antibody  that binds wit h high affinit y andspecificity  to interl eukin 17A (IL-17A) , a 
proinflammatory  cytokine.  Ixekizumab is marketed in the US and EU for the treatment of 
moderate -to-severe plaque psoriasis (Ps) at a dose of 160 mg at Week 0, followed by 80 mg 
every 2 weeks up to Week 12, then maintenance dosing of 80 mg every 4 weeks, a nd for 
psori atic arthrit is(PsA) at a dose of 160 mg at Week 0 fo llowed by 80 mg every 4 weeks .  
Ixekizumab is also marketed in the US for treatment of ankylosing spondylit iswith a 
recommended dose of 160 mg (two 80 -mg inject ions) at Week 0, fo llowed by 80 m g every  
4weeks .
In the ixekizumab clinical program, injection site pain was reported by  2.4% of pati ents wi th 
moderate -to-severe Ps and 1.5% of patients with PsA .  Mo st inject ion site pain occurred shortly  
after drug administration and the incidence rate declined wit h subsequent inject ions.  Post 
approval  reports al ong wi th insights fro m custom ers have shown that pain is a clear concern and 
issue for pati ents, thus the rati onale for evaluat ing an alternate formulat ion to hel p reduce 
inject ion site pain .  
3.3. Benefit/Risk Assessmen t
As thi s study  will enrol lhealt hy subjects, t here is no anticipated therapeutic benefit for the 
subjects.   
On the basis of the 21 Mar 2019 data cutoff dates for the current invest igator’s brochure (IB)
(approved on 7 June 2019) , 
approximately 984 8patients were treated with at least 1 dose of 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 15
LY2439821ixekizumab in clinical trials (6721 patients wi th Ps, 532 patients wi th rheumatoi d arthri tis, 
1413 patients wi th PsA, 253 healt hy subjects, and an estimated 929 patients with axial  
spondylo arthri tis (includes both radiographic and nonradiographic axial spondyloarthrit is).  
Four p revious studies have administer edixekizumab to healthy subjects .  These include Study 
I1F-MC-RHCA (RHCA) where 41 subjects were administer ed ixekizumab by PFS (160 mg 
[2×80 mg] fo llowed by  80 m g 2weeks later) .  All treatm ent-emergent adverse events (TEAEs)
in Study  RHCA were mild in severit y.  The m ost comm only reported adverse events ( AEs)were 
headache (4 events in 4 subjects) ,injection site erythem a(4 events in 2 subjects) , and fat igue (3 
events in 3 subjects) .  With the except ion of fat igue, this is consistent with co mmo nly reported 
AEs reported in Phase 3 studies.  An addit ional 78 heal thy subjects were administ ered 
ixekizumab by  PFS, marketed AI, and modified AI (3 single 80 mg doses) in Study I1F-MC-
RHCK (RHCK) .  In Study  RHCK, a ll TEAEs were mild in severit y and the m ost comm only 
reported Medi cal Dict ionary for Regulatory  Activities ( MedDRA )preferred term was inject ion 
site reacti on(ISR) (which represented solicited AEs) with inject ionsite pruri tus, nausea, 
diarrhea, upper respiratory tract infect ion, and injection site ery thema (nonso licited AEs) also 
reported by  at least 2 subj ects each .  
Study  RHCS was a 3- period crossover design , hence each subject received three 80 m g
inject ions,each separated by  7 days (1 inject ion from each of the 2 al ternate ixekizumab 
formulations [test] and 1 injection from the commerci al ixekizumab form ulation [reference]) .  
Safety data collected during the study , including AEs, clinical laboratory  tests, and vit al signs ,
indicated that all 3 treatments administered were consistent with previous studies wit h 
ixekizumab in healt hy subjects .  The percentage of subjects reporting TEAEs (all causalit ies) 
was generally similar fo llowing administrat ion of each treatment (17.5%to 26.2%) .  The most 
commo nly reported treatm ent-related TEAEs (all causalit ies) were in the General Disorders and 
Administrati on Si te Condi tions system  organ cl ass, wi th ISRs being the most frequently reported 
TEAE overall (18 events in 13 subjects) .  Inject ion site rash , inject ion site hemorrhage , nasal  
congest ion, productive cough, upper respi ratory tract i nfect ion, headache, pain in extremit y, and 
breast m ass were each also r eported by at least 2 subjects .  Infect ions and infestations that were 
considered to be treatment related were reported by  6 subjects overall .The m ajority of TEAEs 
were mild in severit y.  
In Study  RHCT, 99 healthy subjects received a singl e 80-mg SCixekizumab inject ion (33 in 
each group of either the commercial or 2 test formulat ions)
.Safet y data collected during the 
study , including AEs, clinical laboratory  tests, and vital signs ,indicated that all 3 treatments 
administered had similar safet y profile s.  The percentage of subjects reporting treatment -related 
TEAEs was similar fo llowing administration of each treatment (30.3% to 45.5%) .  The m ost 
commo nly reported treatm ent-related TEAEs were in the General Disorders and Administration 
Site Condi tions system  organ cl ass, wi th ISRs being the most fr equent ly reported TEAE overall 
(5 events in 4 subjects ).  Injection site ery thema, abdo minal pain, upper respiratory tract 
infect ion,and headache were each also reported by at least 2 subjects.   The majorit y of TEAEs 
were mild in severit y.Antidrug ant ibody  response observed in Study  RHCT wi th heal thy 
subjects was approximately  9.1%to 12.1% with a low incidence of neutralizing ant ibodies .  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 16
LY2439821In Study RHCT, 2 subjects had a neutrophil count lower than the reference range at 1 postdose 
time point each during the study ; neither of these decreases were clinically  significant.  A 
decrease in neutrophil count is known to occur with IL-17antagonism .One death was reported 
in Study  RHCT in a hospi talized study  parti cipant who had 4 serious AEs ( SAEs ) (sinusitis, 
cerebral vein thrombophlebit is/cerebral vein thro mbosis, periorbital abscess, and 
phaeohypho mycotic brain abscess ).  These 4 SAEs were deemed unrelated to ixekizumab .
More informat ion about the known and expected benefits, risks, SAEs and reaso nably 
anticipated AEs of ixekizumab are to be found in th e IB and the United States P roduct Insert 
(drug l abel) .  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 17
LY24398214.Objectives and Endpoints
Table RHCU .1shows the objectives and endpo ints of the study .
Table RHCU .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the bioequivalence of a single 
80mg SC dose of ixekizumab alternate 
formulation (test) compared to the ixekizumab 
commercial formulation (reference)Cmax, AUC(0 -∞), AUC(0 -tlast)
Secondary
To describe the safet y and tol erabili ty of a 
single 80 mg SC dose of ixekizumab alternate 
formulation (test) com pared to the commercial 
formulation (reference)TEAEs, SAEs
Abbreviations:  AUC(0 -∞) = area under the concentration versus time curve from time zero to infinity; 
AUC(0 -tlast)= area under the concentration versus time curve from time zero to time t, where t is the last time point 
with a measurable concentration; C max = maximum observed drug concentration; SAE = serious adverse event; SC 
= subcutaneous; TEAE =treatment -emergent adverse event.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 18
LY24398215.Study  Design
5.1. OverallDesign   
Infection risk
Parti cipants shoul d follow local guidance and clinical research unit (CRU )precauti ons to 
minimize risk for COVID -19 infect ion.
Study  RHCU is a Phase 1, subject -blind, 2-arm, randomized, parallel -design study  in healt hy 
subjects.  
All subjects will be screened within 28 days prior to enrollment.   Eligible subjects will be 
admitted to the CRU on Day  
-1.  At  screening , subjects will be stratified into 1 of 3 weight 
categori es(<70.0 kg, 70.0to 80.0 kg, >80 .0kg).  Wit hin the 3 weight categories, subjects will be 
rando mized 1:1 to ei ther 80 -mg ixekizumab c ommerci al formulation (reference) or 80 -mg 
ixekizumab alternate formulat ion (test) and subrandomized 1:1:1 to inject ion site (arm, thigh, or 
abdo men) (Table RHCU. 2). On Day  1, subjects will receive a single SC dose according to the 
rando mizat ion plan(Table RHCU. 2and Schedule of Act ivities, Secti on 2).  
The desireis to have approximate lyequal  numbers of subjects in each weight category to avoi d a 
large difference in mean weight between the test and reference formulat ion groups. A subject 
popul ationof 72 per wei ght group i s an approximate target with the recommended weight 
categori es selected based on the distribut ion of weights in the prior studies, RHCS and RHCT. 
The number of subjects assigned to each formulat ion andthe number of subjects assig ned to 
each site of inject ion locationis desired to be balanced .  
Table RHCU. 2
. Study RHCU Stratification and Randomization Plan
Weight Category 
(Subjects)Formulation 
(80-mg ixekizumab)Subcutaneous 
Injection Location aDesired Number of 
Subjects
Low
<70.0 kg
(72subjects)Commercial (reference)Arm12
Alternate (test) 12
Commercial (reference)Abdomen12
Alternate (test) 12
Commercial (reference)Thigh12
Alternate (test) 12
Medium
70.0 kg – 80 .0kg
(72subjects)Commercial (reference)Arm12
Alternate (test) 12
Commercial (reference)Abdomen12
Alternate (test) 12
Commercial (reference)Thigh12
Alternate (test) 12
High
>80.0kg
(72subjects)Commercial (reference)Arm12
Alternate (test) 12
Commercial (reference)Abdomen12
Alternate (test) 12
Commercial (reference)Thigh12
Alternate (test) 12
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 19
LY2439821Abbreviations:  RHCU = I1F -MC -RHC U; SC = subcutaneous.
aA dose of investigational product will consist of 1 SC injection of 80-mg ixekizumab into the arm, thigh, or 
abdomen.  All doses will be administered by trained site staff.
Subjects m ay be all owed to l eave the CRU after complet ing the 4 -hour safet y assessment on 
Day 1, at the invest igator’s discret ion, and will return for PK ,immunogenic ity sampling
,and 
safet y assessments at predefined t imes up to 12 weeks postdose.  Subjects will be monitored for 
safet y between outpatient visits by way of telephone assessment.
Safety and tol erabilit y will  be assessed by  clinical laboratory  tests, vi tal sign measurements, 
temperature, recording of AEs, physical examinat ion (PE)/medical assessments, Columbia 
Suicide Severi ty Rating Scale (C -SSRS) ,andimmunogenicit y.  
Study  governance considerations are described in detail in Appendix 3 .
5.2. Number of Participants   
Up to approximately  240 subjects m ay be enrolled sothat approximately 216subjects complete 
the study  (108 in the 80-mg ixekizumab commercial formulation [reference] group and 108 in 
the 80-mg ixekizumab alternate formulat ion [test]group ) .  
As described in Section 5.1, eligible subjects will be admitted to the CRU on Day  -1.  At 
screening, subjects will be stratified and rando mized as described in Sect ion 5.1and
Table RHCU. 2.  On Day  1, subjects will receive a single SC dose (Schedule of Activit ies, 
Secti on 2)according to the randomizat ion plan.  The number of subjects in each weight category
and assigned to each formulat ionis desiredto be approximately  equal.  The number of subjects 
assigned to each site of inject ion locationis desired to be balanced .  
For purposes of this study , a subject completes the study  when all  scheduled procedures shown 
in the Schedule of Act ivities have been finished.
5.3. End of Study Definition   
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject.
5.4. Scientific Rationa le for Study Design
Conducting the study  in healt hy subjects mit igates the potenti al confounding effects of the 
disease state and concomitant medications in pat ients.  A populat ion of healt hy subjects is 
frequently used in the assessment of the bioequivalence of both sm all and large m olecules.  
Single doses of ixekizumab and the PK sampling time points have been selected to generate PK 
profiles sufficient to fulfill the study  object ives.  
A parallel -group desi gn is chosen because a crossover design is impract ical for ixekizu mab, 
which has a half -life o f approximately  13 days.  Addi tionally , a crossover study  coul d confound 
PK data if subjects develop neutralizing ant idrug ant ibodies (ADAs).  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 20
LY24398215.5. Justification for Dose
The recommended dose for Ps patients is 160 mg by SC inject ion (two 80 -mg inject ions) at 
Week 0, fo llowed by an 80- mg injection at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 
4weeks.  A dose of 80-mg ixekizumab was selected for Study  RHCU to m atch the approved 
individual dose unit strength administered during treatment in clinical pract ice.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 21
LY24398216.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , PE, 
vital signs , clinical laboratory  tests and electrocardiogram (ECG) .  
The nature of any condit ions present at the time of the PEand any preexist ing condit ions will be 
docum ented.   Screening and/or Day  -1 laboratory  testing may  be repeated once at the di scret ion 
of the invest igator for any out -of-range resul ts.  
Screening may occur up to 28 day s prior to enrollment .  Subj ects who are not enrolled within 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm thei r eligibili ty.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or Day -1:
[1] are overtly healt hy males or females, as determined by  screening m edical 
history  and PE, or are males or females wit h chronic, stable medical problems 
that, in the invest igator’s opinio n, will not place the subject at increased risk 
by participat ing in the study , and will not interfere with interpretation of the 
data
[1a] male subjects :
agree to use a reliable method of birth control and to not donate sperm 
during the study  and f or 3 m onths f ollowing ixekizumab dosing .
Examples of reliable methods of birth control ,
for male subjects condoms with spermicide or male sterilizat ion, 
for female partners of childbearing potential, a highly  effect ive 
birth control method, 
ooral or implanted contraceptives, 
ointrauterine device or 
oa combinat ion of 2 effective methods (for example, female 
condom  with spermicide )
.
Male s ubjects who are abstinent (if this is complete abst inence, as their 
preferred and usual lifest yle) or in a same -sex rel ationship (as part of their 
preferred and usual lifest yle) must agree to either maintain abst inence or stay  
in a same -sex rel ationship without sexual relat ionships wit h females .  
Periodic abst inence, declaration of abst inence just for the duration of the 
trial, and wi thdrawal are not acceptable methods of contraception.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 22
LY2439821[1b] female subjects :
1) W omen of child -bearing potenti al who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same -sex relati onship 
(as part of their preferred and usual lifest yle) must agree to either remain 
abstinent or stay  in a same -sex relati onship without sexual relationships with 
males.  Periodic abst inence (e .
g., calendar, ovul ation, symptothermal, 
postovulat ion methods), declarat ion of abst inence just for the duration of the 
trial, and wi thdrawal are not acceptable methods of contraception.
2)Otherwi se, women of child -bearing potential must agree to use 1 highly 
effect ive method (less than 1% failure rate) of contraception or a combinat ion 
of 2 effect ive methods of contraception for the entirety of the study  and f or 
3months fo llowing ixekizuma b dosing .
i. Women of child
-bearing potenti al parti cipat ing must test negative for 
pregnancy prior to init iation of treatm ent as indicated by  a negat ive 
serum  pregnancy  test at the screening visit followed by  a negat ive urine 
pregnancy test on Day  -1.
ii. Either 1 hi ghly effect ive method of contraception ( e.g., combinat ion oral  
contraceptives, implanted contraceptives, or intrauterine device) or a 
combinat ion of 2 effect ive methods (such as male or female condo ms 
with sper micide, di aphragms with spermicide, or cervical sponges) will 
be used.  The subject may choose to use a double -barrier m ethod of 
contraception.  Barrier protection methods without concomitant use of a 
spermicide are not a reliable or acceptable method.  Th us, each barrier 
method must include use o f a spermicide.  It should be noted that the use 
of male and female condo ms as a double -barrier method i s not 
considered acceptable due to the high failure rate when these methods 
are combined.
3)
Women not of child -bearing potential may part icipate and include those who 
are:
i. infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , bilateral  salpingectomy , tubal  ligat ion, or permanent 
tubal  occl usion such as Essure ®), a congenital anomaly such as 
mullerian agenesis ,or
ii. postmenopausal ,defined as eit her:
a) awom an at l east 50 y ears of age with an intact uterus, not 
on horm
one therapy , who has had ei ther:
cessat ion of menses for at least 1 y ear, or
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 23
LY2439821at least 6 months of spontaneous amenorrhea with a 
follicle -stimulat ing horm one level >40 mIU/mL
b) awom an 55 y ears or ol der, not on hormone therapy , who 
has had at least 6 months of spontaneous amenorrhea ;
c) awom an 55 y ears or ol der wi th a diagnosis of menopause 
prior to starting hormone replacement therapy
[2] are aged at least 18 to 75 years at the time o f screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive at screening
[4] have venous access sufficient to allow for blood sampling as per the protocol
[5] are reliable and willing to make themselves available for the duration of the study  and 
are willing to fo llow study  procedures
[6] are able and willing to give infor med consent
6.2. Exclusion Criteria
Subjects will be excluded from study  enro llment if they meet any o f the following cri teria at 
screening and/or Day -1:
[7] are invest igativesite personnel  direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling
[8] areemployees of Eli Lilly  and Com pany  (Lilly )
,Covance , ora third-party
organi zation involved in the study
[9] are currently enrolled in a clinical  study  involving an invest igational product
(IP)or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study   
[10] have participated , within the last 30 days in a clinical study  involving an IP.  
If the previous IPhas a long half -life, 5 half -lives or 30days (whichever i s 
longer) should have passed
[11] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing ixekizumab , and have previously  received the IPor hav e been 
administered other anti-IL-17 agents
[12] have known allergies to ixekizumab , related compounds or any  com ponents of 
the form ulation, or hi story  of significant atopy
[13] have self -perceived dullness or loss of sensation on either side of their arm, 
thigh,or abdomen
[14] have uncontrolled arterial hypertensio n characteri zed by  a systolic bl ood 
pressure >160 mmHg or diastolic blood pressure >100 mmH g
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 24
LY2439821Note:  if an init ial blood pressure reading exceeds this limit, the reading may 
be repeated once after the subject has rested sitting for ≥10minutes.  If the 
repeat val ue is l ess than the cri terion limit s, the second value may be accepted.
[15] have a significant history  of, or current cardiovascular, respi ratory , hepatic, 
renal, gastrointestinal, endocrine, orhematologic disorders , that in the opinion 
of the invest igator poses an unacceptable risk to the subject if participating in 
the study  or of  interfering with the interpretation of data
[16] have p resence of significant uncontrolled neuropsychiatric disorder; have 
lifetime history  of suicidal behavior (y es to any  suici dal behav ior questi on 
from the “Suicidal Behavior” portion of the C- SSRS from screening and 
between screening and baseline [Day -1]); have history  of active suicidal 
ideat ion within the past year (y es to questi on 4 or 5 on the “Suicidal Ideat ion” 
porti on of  the C -SSRS from screening and between screening and baseline 
[Day -1]);and/or are clinically  judged by  the investi gator to be at risk for 
suicide
[17] have recent history  (past 30 days) of depressio n; have Hospi tal Anxiet y 
Depressio n Scale ( HADS )Depressio n subscale score of ≥11
[18] have current or hi story  of inflammatory  bowel  disease (IBD) (Crohn’s disease or 
ulcerat ive co litis), signs or symptoms indicat ive of ulcerative colit is or Crohn’s 
disease (based on invest igator determination), or knowledge of a family history  of 
IBD in first degree relatives
[19] Infections :
[19a] have had a serious infect ion (e. g., pneumonia, cellulit is, and sepsis), 
have been hospitalize d, or have received intravenous ant ibiotics for an 
infect ion within 12 weeks pri or to Day  1; have had a serious bone or 
joint infect ion within 24 weeks pri or to Day  1, or have ever had an 
infect ion of an artificial jo int; or are immunocompromised to an ext ent 
such that participat ion in the study  woul d pos ean unacceptable risk to 
the subject
[19b] have or have had an infect ion typical of an immunocompromised host 
and/or that occurs with increased incidence in an immunocompromised 
host (including, but not limited to, pneumocyst is jiroveci pneumonia, 
histopl asmosis, or cocci dioidomycosis), or have a known 
immunodeficiency
[
19c] have or have had a herpes zoster infect ion or any  other clinically 
apparent varicella -zoster vi rus infecti on wi thin 12 weeks of Day  1
[
19d] h ave had any  other active or recent infection within 4 weeks of Day  1 
that, in the opinio n of the invest igator ,would pose an unacceptable risk 
to the subject if part icipating in the study ; these subjects may be 
rescreened (once) ≥4weeks after documented resolut ion of symptoms
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 25
LY2439821[20] have a history  of unco mpensated heart failure, fluid overload, or myocardial 
infarction, or evidence of new -onset i schemic heart disease or other serious 
cardi ac disease, wi thin 12 weeks pri or to Day  1
[21] have clinical laboratory  test resul ts at screening that are outside the normal 
reference range for the populat ion and are consi dered clinically  significant, 
and/or have any of the fo llowing specific abnormalit ies:
 neutrophil count <1500 cells/µL
 lymphocy te count <800 cells/µL
 platelet count <100,000 cells/µL
 total white blood cell  count <3000 cells/µL
Note:  Screening and/or Day -1 laboratory  testing may be repeated 
(once )at the discretion o f the invest igator for any out of range 
results.  Thereafter, laboratory  tests may  not be repeated unl ess 
there is a documented technical error or cl inical reason to believe a 
resul t may  need to be retested within the screening period
[22] regularly use known drugs of abuse and/or show posit ive findings on drug 
screening
[23] show evidence of human immunodeficiency  virus (HIV) infection and/or 
positive HIV ant ibodies
[24] show evidence of hepatit is C or positive hepat itis C ant ibody
[25] show evidence of , or test posit ive for,hepatit is B and/or posit ive hepat itis B 
surface ant igen and/or hepati tis B core antibody
[26] are wom en who are lactating
[27] have donated blood of more than 500 mL within the last month prior to dosing 
or intend to donate blood during the course of the study
[28] have an average weekly  alcohol  intake that exceeds 21 units per week (males
up to age 65 ) and 14 units per week (females up to and over 65, and males 
over 65 ), or are unwilling to stop alcoho l consumpti on for 48 hours pri or to 
admission t o the CRU until CRU discharge, plus 48 hours prior to admissio n 
to the CRU for the 12 -week fo llow-up visit unt il final discharge fro m the 
CRU, or are unwilling to restri ct alcohol  intake to 3 units per day  (males) and 
2 uni ts per day  (females) during the o utpatient period (1 uni t = 12 oz or 
360mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of dist illed spirits)
[29] show evidence of active or latent tuberculosis (TB) , as documented by 
medical history  and examinat ion,any recent chest x -rays (if obtained in the 
previous 6 months; x -rays will not be taken for the sole purpose of 
determining eligibilit y for this study ), and TB testing
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 26
LY2439821[30] had a vaccinat ion with Bacillus Calmette -Guérin (BCG ),other livevaccines , 
or attenuated live vaccines within 12 mo nths prior to admissio n to the CRU , 
or intend to have a vaccinat ion with BCG during the course of the study , or 
within 12 m onths of co mpleting treatment in this study
[31] have received treatment with bio logic agents (such as monoclonal ant ibodies , 
including marketed drugs ) within 3 m onths or 5 half -lives (whichever is 
longer) prior to dosing
[32] intend or are likely  to use over -the-counter o r prescript ion medication for pain 
orinflammation wit hin 7 days prior to dose administration .  Subj ects on stabl e 
doses of other medicat ions (e.g., statins and ant ihypertensives) may be eligible 
for enrollment following discussio n with the sponsor (Section 7.7)
[33] have a known allergy or hypersensit ivity to any  biologic therapy  that woul d 
pose an unacceptable risk to the subject if participating in this study
[34] have had any  malignancy wit hin the past 5 y ears, except for basal cell or 
squamous epithelial carcino mas of the skin that have been resected with no 
evidence of metastatic disease for 3 y ears
[35] have any condit ion that coul d affect pain percept ion from an inject ion
[36] have excessive tattoos or scars over the arm, thigh, or abdomen or other 
factors (e .g., rash, excessive fo lds of skin) that, in the invest igator’s opinio n, 
woul d interfere wi th inject ionsite assessments
[37] in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study
6.2.1. Rationale for Exclusion of Certain Study Candidates
Exclusio n Cri teria [7] and [ 8] prevent conflict of interest in study  parti cipants.  Exclusio n 
Criteria [ 9] through [ 37] exclude items incl uding, but not limited to ,medical condi tions, 
medicat ion intolerance, and concomitant medicat ion use that may confound the assessment of 
study  endpoints .  
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , 
subjects m ay undergo medical assessment sand review of compliance with 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Subjects may receive a light meal (beforedosing) on Day  1 but will be fasted (water is 
permitted) f rom 1 hour pri or to dosing unt il 1 hour postdose.  Standard meals will be provided at 
all other times while subjects are resident at the CRU, per the CRU’s po licy.
6.3.2. Alcohol and Tobacco
Alcoho l consumpt ion is not permi tted while at the CRU and for 48 hours pri or to each study visit .  
Alcoho l intake during outpatient periods should not exceed 3 units per day (males up to age 65 ) 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 27
LY2439821and 2 units per day  (females up to and over 65, and males over 65 ).  In addit ion, subjects must 
abide by  the CRU sm oking restri ctions during study visits and while resident in the CRU .  
6.3.3. Activity
Subjects will be encouraged to maintain their regular exercise; however, they should not 
undert ake vigorous or prolonged exercise wit hin 48 hours prior to each CRU visit.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure ) may be re -
screened (once )at the invest igator’s discretion (See Section 6).  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 28
LY24398217.Treatment
7.1. Treatment Administ ered
A dose of IP will consist of 1 SC inject ion of 80 -mg ixekizumab in a 1 -mL volume into the arm, 
thigh, or abdomen.  All doses will be administered by trained site staff.
This study  involves a comparison of:  
80-mg ixekizumab commercial formulation (reference ) administered subcutaneously via 
AI
80-mg ixekizumab alternate f ormulation (test) administered subcutanenously via AI
Prior to the injectio n using the AI, the invest igator or his/her designee will clean the subject ’s 
skin. Theinject ion will be administered by trained site staff, according to the instructions 
provi ded by the sponsor .
Table RHCU. 3shows the treatment regimens.
Table RHCU. 3
. Treatments A dministered
Treatment Name Alternate Formulation (Test) Commercial Formulation (Reference)
Formulation solution for injection solution for injection
Dose 80-mg ixekizumab 80-mg ixekizumab
Route of Administration SC injection SC injection
Delivery Method AI AI
Abbreviations:  AI= autoinjector ; SC = subcutaneous.  
The invest igator or designee is responsible for :
explaining the correct use of the IPsto the si te personnel
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
and returning all unused medicat ion to Lilly or its designee at the end of the study
where appropriate
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified a nd documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .  Retentio n samples must be kept as instructed by  
Lilly .  
7.1.1. Packaging and Labeling
Ixekizumab will be supplied by the sponsor or its designee in accordance with current good 
manufacturing practice , labeled according to the country ’s regul atory  requi rements, and supplied 
with lot numbers, expiry  dates, and certificates of analysis, as applicable.  Each ixekizumab AIis 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 29
LY2439821designed to deliver 80 mg of ixekizumab.  The fo llowing products will be supplied by Lilly ,with 
study -specific labels, for use in the study :
ixekizumab commercial formulation (reference; solut ion for inject ion)inan AI(80-
mg ixekizumab in a 1-mL volume)
ixekizumab alternate formulation (
test; solution for injecti on) in an AI (80-mg 
ixekizumab in a 1-mL volume)
Unblinded site personnel will be responsible for handling and administering IP.  Unblinded site 
personnel are also responsible to make sure subjects remain blinded to treatment .  Site personnel 
may create blinding processes and precautions as they deem necessary  to m aintain inject ion site 
assessor blinding
.
The IPwill be labeled according to the country’s regulatory  requi rements.
7.2. Method of Treatment Assignment
The rando mizat ion table will be prepared by the statist ician (or appropriate delegate) for the 
study  and provi ded to the CRU pharmacists or pharmacy  staff  involved in dose preparation.
As described in Section 5.1, eligible subjects will be admitted to the CRU on Day  -1.  At 
screening, subjects will be stratified into 1 of 3 weight categories (<70 .0kg, 70.0 to 80.0kg, 
>80.0kg).  Within the 3 weight categories, subjects will be rando mized 1:1 to either 80
-mg 
ixekizumab co mmercial formulat ion (reference) or 80 -mg ixekizumab alternate formulation 
(test) and subrando mized 1:1:1 to injection site (arm, thigh, or abdomen) ( Table RHCU. 2).  
7.2.1. Selection and Timing of Doses
The actual  time of dose administration will be recorded in the subject’s case report form (CRF).
7.3. Blinding
Study  RHCU is a subject -blind study .
7.4. Dose Modification
Dose adjust ments are not allowed in this study .
7.4.1. Special Treatment Considerations
All biological agents carry  the risk of systemic allergi c/hypersensit ivity reacti ons.  Clinical  
manifestations of these reactions may include, but are not limit ed to skin rash, pruritus (itching), 
urticaria (hives), angioedema ( e.g., swelling of the lips and/or tongue), and anaphylact ic reactio n.  
Sometimes these react ions can be life threatening.  Proteins may also cause redness, itching, 
swelling, or pain locally at the inject ion site.  Therefore, all subjects should be closely  monitored 
for signs or symptoms that could result from such reacti ons, be educated on the signs or 
symptoms of these ty pes of  react ions, and be instructed to contact the study  site immediately if 
any of the symptoms are experienced after discharge fro m the CRU
.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 30
LY2439821If a subject experience s an acute allergic/hypersensit ivity reacti on after an inject ion of IP, he or 
she should be managed appropriately and receive relevant supportive care.  The event should be 
recorded as an AE .  Incase of syste mic hypersen sitivi ty react ions, defined as anaphylaxis or 
generalized urticaria, ad ditional bl ood sam ples shoul d be collected as close as possible to the 
onset of the event (Section 9.2.1.3 ). Follow -up samples should be obtained at the next regularly 
scheduled visit or 4 weeks after the event , whi chever is l ater.  The l ab resul ts are provided to the 
sponsor via the central labor atory .  
7.5. Preparation/Handling/Storage/Accountability
Invest igational product will be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original 
carton to protect from light.  Invest igational product shoul d not be frozen or shaken.  
Sites will be required to monitor the temperature of the on -site storage condi tions of  the IP.  The 
investigator or designee must confirm appropriate temperature condit ions have been maintained, 
as communicated by the sponsor, during transit for all IP received and ensure any discrepancies 
are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study  may receive IP or study  materials, and only authorized 
site staff may supply IP.  All IP sh ould be stored in an environmentally  controlled and m onitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff.
The invest igator is responsible for study treatmen t accountabilit y, reconciliat ion, and record 
maintenance (such as receipt, reconciliat ion, and final disposit ion records).
7.6. Treatment Compliance
TheIPwill be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
Subjects on stable conco mitant m edicat ion at the time of study  entry  shoul d continue their 
regul ar, unchanged dose throughout the study .  Permitted concomitant medicat ions, at the 
discreti on of  the invest igator, include horm onal contraceptives, hormone replacement therapy , 
and thy roid repl acement .  In addition, occasional acetamin ophen is acceptable at the discretion of 
the invest igator.  However, acetaminophen should not be administered on the dosing day wit hin 
4hours prior to the inject ion and unt il at least 4 hours after the inject ion.  No m ore than 3 g of 
acetaminophen will be permitted in any  24-hour peri od.  Incl usion of subjects on any  other 
concomitant medicat ion (e.g., statins and ant i-hypertensives) is cont ingent upon approval 
following consultation wit h the sponsor.
Subjects will be restricted fro m applying any  creams or lotions on the arm, thigh, or abdominal 
skin within 24 hours prior to or after the inject ion.
If the need for any  addi tional concomi tant m edicatio n arises, inclusion or continuat ion of the 
subject may be at the discret ion of the invest igator after consult ation wi th a Lilly Clinical 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 31
LY2439821Pharmaco logist (CP) or Clinical Research Physician (CRP).  Any medication used during the 
course of the study  must be docum ented.
7.8. Treatment after the End of the Study
Not applicable .
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 32
LY24398218.Discontinuation Criteria
Subjects discont inuing fro m the treatm entprematurely for any reason shoul d complete AEand 
other fo llow-up procedures per Section 2of this protocol .
8.1. Discontinuation from Study Treatment
Not applicable .
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the s ponsor or invest igator ident ifies a subjec t who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the subject may cont inue in the study .  If both agree i t is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled subject to continue in the study .  
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
enrollment in any other clinical study  involving an IPor enrollment in any other ty pe 
of medical research judged not to be scientifically or medically compat ible with this 
study prior to receiving IP in this study .  If the subject has received IP, they  will 
continue to be monitored for safet y for the pl anned durati on of  the study .
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
investi gator decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
subject decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subject swho fail to return for a s cheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 33
LY24398219.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
Not applicable.  
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through a n appropriate healt h care option, 
AEs that are serious or otherwise medically important, orconsidered related to the IPor the 
study .  The subject should be followed unt il the event resolves, stabilizes with appropri ate 
diagnosti c evaluat ion, or is reason ably explained.  The frequency of follow -up evaluat ions of the 
AE is left to the di screti on of  the invest igator.
The invest igator will record all relevant AE and SAE informat ion in the electronic CRF (eCRF).  
After the informed consent form is signed, study  site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  Addi tionally , site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , study  device, or a study procedure, takinginto account the 
disease, co ncomitant treatm ent or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IP, study device and/or study procedure and the AE .
Planned surgeries should not be repo rted as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 34
LY24398219.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hos pitalizat ion
a life- threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe subject or may requi re interventi on to prevent 
one of the other outcomes listed in the definit ion above
when a condit ion related to the auto injector necessitates medical or surgical intervent ion 
to preclude eit her permanent impai rment of  a body funct ion or perm anent dam age to a 
body  structure, the seri ous outcom e of “requi red intervent ion” will be assigned
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
pract ically possible.
Additionally, study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Although all AEs are recorded in the eCRF after signing informed consent, SAE repo rting to the 
sponsor begins after the subject has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed consent, but prior to receiving IP, AND is considered 
reasonably  possibly  r elated to a study  procedure then it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study  (the subject summary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any  time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
Pregnancy (maternal or paterna l exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Adverse Events of Special Interest
The fo llowing AEs of special interest will be used to determine the safet y and tol erabilit y of 
ixekizumab administered by  AIin this clinical study.
Adverse events of special interest for ixekizumab are:
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 35
LY2439821cytopeni as (leukopenia, neutropenia, and thrombocy topeni a)
liver funct ion test changes/enzyme elevat ions (alanine aminotransferase [ ALT ], 
aspartate aminotransferase [ AST ], total bilirubin level [ TBL ], and alkaline 
phosphatase [ ALP])that are consid ered to be clinically relevant by the principle 
investigator /invest igator )
infect ion
ISRs (see Section 9.4.5.1 )
allergic reactions/hypersensit ivities
cerebrocardiovascular events
malignancies
depressio n
IBD (Crohn’s disease and ulcerative co litis)
interstitial lung disease
If infections, or allergic/hypersensit ivity react ions are reported, these will be recorded as AEs .  
Invest igators will also educate subjects about the symptoms of allergic/hypersensit ivity reacti ons 
and will provide instructions on dealing with these reactions.  A blood sample will be co llected 
when possible for any subject who experiences an AE of systemic hypersensit ivity react ion 
during the study .
Data on cerebrocardiovascular events (defined as death, myocardial infarct ion, stroke, 
hospi talizati on for unstable angina, hospitalization for heart failure, coronary  revascularizat ion 
procedure, peripher al revasculari zation procedure, cardi ogenic shock due to my ocardial  
infarction, resuscitated sudden death, serious arrhythmia, hospitalizat ion for hypertensi on, and 
peripheral  arteri al event) will be collected and the events may be adjudicated by  an extern al 
Clinical Events Co mmit tee (CEC) m ade up of a chair, 2 cardio logists, and a neurol ogist.  
Data on suspected IBD, as identified by events possibly indicat ive of ulcerative colit is and 
Crohn’s disease, will be co llected .  The events may be adjudicated by  an external CEC 
composed of gastroenterologists with expert ise in IBD.  
The rol e of the CECs is to adj udicate defined clinical events, in a blinded, consistent, and 
unbiased manner throughout the course of a study .  The im portance of the CECs i s to ensure that 
all events that have been reported are evaluated uniformly by a single group.
9.2.1.2. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated det ailed guidances.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 36
LY24398219.2.1.3. Systemic Hypersensitivity Reactions
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons. If such a react ion occurs, a dditional data describing each symptom should be provide d
to the sponsor in the eCRF . 
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are re ceiving study  drug .  It is recommended that participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .  
In case of syste mic hypersensit ivity react ions, defined as anaphylaxis orgeneralized urticaria ,
additional blood sam ples shoul d be co llected as described in Appendix 6 .Laboratory results are 
provi ded to the sponsor via the central laboratory.
9.2.2. Com plaint Handling
Lilly co llects product complaints on IPs and drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements .
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the IPor drug delivery system so that the si tuation can be assessed .
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
product complaint process in accordance wit h the instructions provided for this study :
recording a complete descript ion of the product complaint reported and any 
associ ated AEs u sing the study -specific co mplaint forms provided for this purpose
faxing the completed Product Complaint Form wit hin 24 hours to Lilly or its designee
If the invest igator is asked to return the product for invest igation, he/she will return a copy  of the 
Product Com plaint Form  with the product.
9.3. Treatment of Overdose
For the purposes of this study, an overdose of ixekizumab is considered any  dose higher than the 
dose assigned through rando mizat ion.  Autoinjectors used in this study  can deliver only  1-mL 
volume of ixekizumab.
There i s no specific antidote for ixekizumab.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the Taltz Product Label (FDA resources page [WWW] ).
9.4. Safety
Safety will be assessed throughout the course of the study  at si te visi ts and via telephone calls in 
between site visit s.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 37
LY24398219.4.1. Laboratory Tests
Foreach subject, l aboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).  
See Appendix 6 for further l
aboratory  testing and i nstructi ons for hypersensit ivity events.  
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor, if a central vendor is used for the study .
9.4.2. Vital Signs
For each subject, vital signs m easurements shoul d be conducted according to the Schedule of 
Activities (Secti on 2).  
Blood p ressure and pulse rate should be measured after at least 5minutes sitting.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  If orthostatic measurements are required, subjects sho uld be supine 
for at least 5 minutes and stand for at least 2 minutes.   
If the subject feels unable to stand, supine 
vital signs only  will be recorded .  
Addit ional vital signs may be m easured during each study  period if warranted.
9.4.3. Electrocardiograms
For each subject, a single12 -lead di gital ECG will  be collected according to the Schedule of 
Activities(Secti on 2).  
Electrocardiograms must be recorded before collecting any blood s amples.  
Subjects must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion.  Electrocardi ograms m ay be obtained at addit ional times,when deemed 
clinically necessary .  All ECGs recorded should be stored at the invest igational site.
Electrocardiograms will be interpreted by  a qualified invest igator (physician or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
9.4.4. Temperature
Body  temperature will be assessed at the times indicated in the Schedule of Activit ies (Secti on 2).
9.4.5. Other Tests
9.4.5.1. Injection Site Assessments
Inject ion site 
reacti onswill be ca ptured on the ISR AE form and the eCRF as an AE. The 
findings of ISR (incl uding indurati on, pain, edema , pruri tus, and ery thema) fora specific 
inject ion will be captured as a single AE, even if more than 1 of the findings is positive, and the 
,)0&5+&8E&OLQLFDO3KDUPDFRORJ\3URWRFRO 3DJH
/<VHYHULW\WK DWLVUHFRUGHGRQWKH ,65$( IRUPZLOOEHWKHKLJKHVWV HYHULW\DFURVVWKHILQGLQJVDW
HDFKDSSOLFDEOHYLVLW
,ILQMHFWLR QVLWHSDLQLVUHSRUWHG DWDQ\WLPHGXULQJWKHVWXG\  WKHLQWHQVLW\ RISDLQZLOOEH
TXDQWLILHGXVLQJWKHPPYDOLGDWHGY LVXDODQDORJVFDOH9$6 SDLQVFRUH7KH9$6LVD
ZHOOYDOLGDWHGWRRO :LOOLDPVRQDQG+RJJDUWWRDVVHVVLQMH FWLRQVLWHSDLQLWL VSUHVHQWHGDV
DPP OLQHDQFKRUHGE\YHUEDOGHVFULSWRUVXVXDOO\ ͆QRSDLQ͇DQG͆ZRUVWSRVVLEOHSDLQ ͇
7KHVXEMHFWZ LOOEH DVNHGWRUDWHDQ\SDLQDWWKHLQMHFWL RQVLWHRQDVFDOHRIWR PPRQWKH
OLQHDVVRRQDVL VSUDFWLFDOIROORZLQJUHSRUWLQJRIWKHHYHQW
,QMHFWLRQVL WHDVVHVVPHQWVVKRXO GEH FRQGXFWHGDWWKHQH[ WSODQQHGYLVLWIROOR ZLQJWKHUHSRUWLQJ
RIDQ LQMHFWLR QUHODWHG$(
 %OHHGLQJ%UXLVLQJ$VVHVVPHQW
7KHSUHVHQFHRIYLVLEOHEOHHGLQJDWWKHLQMHFWLR QVLWHZLOOEHUHFRUGHGRQWKHH&5)DVDSSOLFDEOH
$EDQGDJH PD\EHSODFHGRQWKHLQMHFWLRQVLWHDIWHUDVVHVVPHQW
 &ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH
&ROXPELD6XLFLGH6HYHULW\ 5DWLQJ6FDOH$VFDOHWKDWFDSWXUHV WKHRFFXUUHQFHVHYHULW\DQG
IUHTXHQF\RIVXLFLGDOLGHDWLRQDQGRUEHKDYLRUGXULQJWKHDVVHV VPHQWSHULRG7KHVFDOHLQFOXGHV
VXJJHVWHGTXHVWLRQVWRVROLFLWWKHW\SHRILQIRUPDWLRQQHHGHGW RGHWHUPLQHLIVXLFLGDOLGHDWLRQ
DQGRUEHKDYLRURFFXUUHG$Q\RFFXUUHQFHRIVXLFLGHUHODWHGWK RXJKWVDQGEHKDYLRUVZLOOEH
DVVHVVHGDWWKHWLPHV LQGLFDWHGLQWKH6FKHGXOHRI$FW LYLWLHV6HFWLRQ XVLQJWKH&66567KH
&6656LVDGPLQLVWHUHGE\DQDSSURSULDWHO\WUDLQHGKHDOWKFDUHS URIHVVLRQDOZLWKDWOHDVW\HDU
RISDWLHQWFDUHFOLQLFDOH[SHULHQFH
7KHQRQOHDGLQJ$(FROOHFWLR QVKRXOGRFFXUSUL RUWRWKHFROOHFWL RQRIWKH&6656,ID
VXLFLGHUHODWHGHYHQWLVGLVFRYHUHGGXULQJWKH&6656EXWZDVQ RWFDSWXUHGGXULQJWKH
QRQOHDGLQJ$(FROOHFWLRQVL WHVVKRXOGQRWFKDQJHWKH$(IRUP ,IDQHYHQWLVVHULRXVRUOHDGVWR
GLVFRQWLQXDWLRQW KLVLVDQH[FHSWLRQZKHUHWKH6$(DQGRU $(OHDGLQJ WRGLVFRQW LQXDWLRQVKRXOG
EHLQFOXGHGRQWKH$(IRUPDQGWKHSURFHVVIRUUHSRUWLQJ6$(VV KRXOGEHIROORZHG7KHIL UVW
WLPHWKHVFDOHLVDGPLQLVWHUHGLQWKLVV WXG\WKH& 6656µ%DVHO LQH± 6FUHHQLQJ¶YHUVLRQ ZLOOEH
XVHGDQGWKHILQGLQJVZLOOFRQVWLWXWHWKHEDVHOLQHDVVHVVPHQW 7KH&6656µ6LQFH/DVW9LVLW¶
VFDOHZLOOEHXVHGIRUDOOVXEVHTXHQWDVVHVVPHQWV7KH/LOO\6 HOI+DUP6XSSOHPHQWVKRXOGEH
FRPSOHWHGHYHU\WLPHWKH& 6656LVDGPLQLVWHUHG,IWKHUHDUH SRVLWLYHILQGLQJVRQWKH
6HOI+DUP6XSSO HPHQWWKHQWKH/LOO\ 6HOI+DUP)ROORZ8SIRUPZLOOE HXVHGWRFROOHFW
DGGLWLRQDOLQIRUPDWLRQWRDOO RZIRUDP RUHFRPSOHWHDVVHVVPHQWRIWKHVHEHKDYLRUV
 +RVSLWDO$Q[LHW\'HSUHVVLRQ6FDOH
7KH+$'6GHSUHVVLRQVXEVFDOHLVDLW HPDVVHVVPHQWVFDOHWKDW GHWHUPLQHVWKHOHYHOVRI
GHSUHVVLR QWKDWDVXEMHFWLVH[SHULHQFLQJRYHUWKHSDVWZHHN 7KH+$'6GHSUHVVLRQV XEVFDOH
XWLOL]HVD SRLQW/LNHUWVFDO HHJWRIRUHDFKTXHVWLRQ DQGLVLQWHQGHGIRUDJHVWR
 \HDUV=LJPRQGDQG6QDLWK:KLWHHWDO7KHVFRU HFDQUDQJHIURPWRZLWK
KLJKHUVFRUHVLQGLFDWLQJJUHDWHUGHSUHVVLRQ=LJPR QGDQG6QDLWK 6QDLWK
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 39
LY24398219.4.6. Safety Monitoring
The Lilly CP or CRP/scient ist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CP or 
CRP will periodically review trends in safety  data, labora tory analy tes, and AEs.
When appropriate, the Lilly CP or CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
9.4.6.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X upper limit of normal ( ULN ), ALP ≥2X ULN, 
or elevated total  bilirubin ≥2X ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to5 
days including ALT, AST, ALP, TBL, direct bilirubin , gamma -glutamyl transferase ( GGT ),and 
creatinine kinase to confirm  the abnorm ality and to determine if i t is increasing or decreasing.  If 
the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the 
investigator based on consultation with the Lilly CPor CRP .  Moni toring shoul d continue unt il 
levels norm alize and/or arereturn ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur :  
elevation of serum  ALT to ≥ 5X ULN on 2 or more consecutive blood tests
elevated serum TBL to ≥ 2X ULN (except for case s of known Gilbert’s syndro me)
elevation of serum  ALP to ≥ 2X ULN on 2or more consecutive blood tests 
subject discontinued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepatic event considered to be a nSAE
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2), serum samples of 
approximately  3mL each will be co llected to determine the serum concentrations of ixekizumab .  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between both the investigator and sponsor.  Instructions for the 
collect ion and handling of blood samples will be provided by the sponsor.  The actual date and 
time (24-hour clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a laboratory approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of ixekizumab will be assayed using a validated enzyme- linked immunosorbent 
assay ( ELISA )method.  
Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
1 year fo llowing last subject visit for the study.  During this t ime, samples remaining after the 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 40
LY2439821bioanalyses may  be used for exploratory metabo lism studi es or exploratory analyses such as 
bioanalyt ical assay  validati on or cross -validation exercises.
9.6. Pharmacodynamic s
Not applicable.  
9.6.1. Immunogenicity Assessments 
At the visit s and t imes specified in the Schedu le of Act ivities (Secti on 2),venous blood samples 
will be co llected to determine ant ibody  producti on against ixekizumab .  
Antibodies may be 
further ch aracteri zed for their abilit y to neutralize the act ivity of ixekizumab.  To interpret the 
resul ts of immunogenicit y, a venous blood sample will be co llected at the same time points to 
determine the serum concentrati ons of ixekizumab . All samples for immunogenicit y shoul d be 
taken predose when applicable and possible.
Treatment -emergent ADAs (TE-ADAs) are defined in Sect ion 10.3.3 .  If the immunogenicit y 
titerat the last scheduled assessment or discont inuation visit is TE-ADA posit ive, additional 
samples may be taken until the signal returns to baseline (i.e. ,no longer TE -ADA posit ive)or for 
up to 1 year after dosing .
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected by  the 
sponsor.  The duration allows the sponsor to respond to future regulatory  requests rel ated to the 
IP.  Any samples remaining after 15 y ears will  be destroy ed.  
9.7. Genetics
A blood sam ple (10 mL) will be co llected for pharmacogenetic analysis as specified in the 
Schedule of Act ivities, where l ocal regul ations allo w.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
ixekizumab and to invest igate genet ic variants thought to play a role in autoimmune di sorders .  
Assessment of variable response may  include evaluati on of  AEs or differences in efficacy.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igativesite personnel .  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local regulat ionsand/or ERBs/IRBs impose shorter time limit s, for the study  at a 
facilit y selected by Lilly or i ts desi gnee .  This retent ion peri od enables use of new techno logies, 
response to regulatory  quest ions, and invest igation of variable response that may not be observed 
until later in the devel opment of ixekizumab.   
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 41
LY2439821Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.  
9.8. Biomarker s
Not applicable .
9.9. Health Economics
Not applicable .
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 42
LY243982110. Statistical Considerations an d Data Analysis
10.1. Sample Size Determination
Upto approximately 240subjects m ay be enrolled sothat approximately 216subjects (108 in the 
80-mg ixekizumab co mmercial formulation [reference ]group and 108 in the 80-mg ixekizumab 
alternate form ulation [test]group) complete the study .  
A sample size o f 108subjects per treatm ent group will provide a pproximately 90% power that 
the 90% confidence interval (CI)of the geom etric mean rati o of maximum observed drug 
concen tration (Cmax) and area under the concentration versus time curve ( AUC )between groups
will fall wit hin equivalence range of 0.8 to 1.25.  This sample size calculation was based on the 
assumpt ions that the PK parameters have log -normal  distribut ion, the percent coefficients of 
variat ion (%CV) of Cmaxand AUC are less or equal to 48% (from study RHCT), the expected 
ratio of geometri c means is between 0.997 to 1.04, and the %CV are the same for subjects from  
each treatm ent group.
Subjects who are randomized but not administered treatment and subjects who do not complete 
PK sampling (including day 85) may be replaced sothat approximately 216 subjects ( 108 for 
each treatment) complete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study .  
10.2.2. Study Participant Characteristics
The subjects’ age, sex, weight, height, BMI, race, site of inject ion, and other demographic 
characterist ics will be recorded and summarized using descript ive statist ics.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee .
Pharmacokinet ic(PK) analyses will be conducted on data from all subjects who receiv ethe
complete single dose of ixekizumab and have suffici ent evaluable PK .  Only subjects who 
complete the PK sampling schedule to Day 85 will be included in the statistical analysis of PK 
param eters .  
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate ,and s tudy 
resul ts may be pool ed wi th the resul ts of other studies for populat ion PKanalysis purposes to 
avoid issues with post hoc analyses and inco mplete di sclosures of analyses.   
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 43
LY243982110.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summ arized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with IPas perceived by the invest igator.  Symptoms reported to occur prior to study  entry  will be 
distinguished from those reported as new or increased in severit y during the study .  Each 
symptom  will be classified by  the m ost sui table term fro m MedDRA .
The number of IP-related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters t hat will be assessed include safety lab oratory parameters and vital signs 
param eters.  The param eters will  be listed and summarized using standard descriptive statist ics.  
Addit ional analysis will be performed if warranted upon review of the data.
10.3.1.2.1. Statistical Evaluation of Other Safety Parameters
Safety laboratory param eters and vital signs data will be listed and summarized using standard 
descript ive statistics, where possible.  Suicidal ideation and/or behavior and self -injurious 
behavior with no suicidal intent, based on the C -SSRS, will be listed by subject.  Only subjects 
that show suicidal ideat ion/behavior or self -injuri ous behavior without suicidal intent will be 
included in the list ing (i .e., if a subject’s answers are all ‘no’ for the C -SSRS, then that subject 
will not be displayed).  Hospital Anxiet y Depression Scale item scores will be listed for subjects 
with HADS depressio n subscale ≥11 at any  time.  Addit ional analysis may  be perf ormed if 
warranted upon review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for ixekizumab will be calculated by  standard 
nonco mpart mental methods of analysis.
The primary  parameters for analysis will be Cmax,AUC(0 -tlast)and AUC (0-∞) of ixekizumab .  
Other noncompartmental parameters, such as time to m aximum drug concentration (tmax),
half-lifeassoci ated wi th the terminal rate constant in noncom partm ental  analysis (t 1/2), apparent 
clearance, and apparent volume of distribut ion may be reported.  
Pharmacokinet ic parameters may also be normalized by  body weight for summarizing the data 
and may  be summarized by  site of inject ion location using descriptive statist ics.  
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter swill be eval uated to determine the bioequivalence of ixekizumab 
alternate form ulation (test) compared to the ixekizumab co mmercial formulat ion (reference) .  
Log-transform ed C maxand AUC parameters will be evaluated in a linear mixed -effects m odel 
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 44
LY2439821with fixed effects for formulationand a ra ndom effect for subject .  The treatm ent differences will 
be back-transform ed to present the ratios of geometric means and the corresponding 90% CI.  
The t maxwill be analyzed using a Wilcoxon rank sum test.  Estimates of th e median difference 
based on th e observed m edians, 90% CIs and p -values from the Wilco xon rank sum test will  be 
calculated.
Bioequivalence will be concluded if the 90% CI is com pletely contained within the interval 
(0.80, 1.25).
10.3.3. Evaluation of Immunogenicity
The frequency and percentage of subjects wi th preexist ing ADA
sandwith TE-ADA sto 
ixekizumab will be tabulated . Treatment -emergent ADAs are defined as those with a titer 2 -fold 
(1 dilut ion) greater than the m inimum required dilution if no ADAs were detected at baseline 
(treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter compared to 
baseline if ADAs were detected at baseline (treatment -boosted ADA). For the TE -ADA 
subjects ,the distribut ion of maximum t iters will be described.   The frequency o f neutralizing 
antibodies will also betabulated in TE -ADA subjects .
The relat ionship between the presence of ant ibodies and the safet y and PKparam eters to 
ixekizumab may be assessed.
10.3.4. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP /investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 45
LY243982111. References
Snait h RP. The Hospital Anxiet y and Depressio n Scale. Healt h Qual Life Outcomes. 2003;1:29 .
Taltz (ixekizumab) Inject ion Label. Food and Drug Administration web site. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125521s016lbl.pdf. Accessed 
October, 22 2019.
White D, Leach C, Sims R, Atkinson M, Cottrell D. Validat ion of the Hospital Anxiet y and 
Depressio n Scale for use with ado lescents. Br J Psychiatry . 199 9;175:452 -454.
Williamson A, Hoggart B. Pain: a review o f three commo nly used pain rat ing scales. J Clin Nurs. 
2005;14(7):798 -804.
Zigmond AS, Snai th RP. The Hospi tal Anxiet y and Depressi on Scale. Acta Psy chiatr Scand.
1983;67 (6):361-370.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 46
LY243982112. Appendices
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 47
LY2439821Appendix 1. Abbreviations and Definitions
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 48
LY2439821Term Definition
%CV percent coefficients of variation
ADA antidrug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
AI autoinjector
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
BCG Bacillus Calmette -Guérin
blinding A procedure in which one or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investigator and/or his /herstaff are aware of the 
treatment but the subject is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/ or his/herstaff and the subject are not.  A double -blind study  is one 
in which neither the subject nor any of the investigator sor sponsor staff who are involved 
in the treatment or clinical evaluation of the subjects are aware of the treatment received
BMI body mass index
CEC Clinical Events Committee
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality  requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 49
LY2439821CP Clinical Pharmacologist
CRF case report form
CRP Clinical Research Physician :  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be p erformed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU clinical research unit
C-SSRS Columbia Suicide Severity Rating Scale
ECG electroc ardiogram
eCRF electronic case report form
ELISA enzyme-linked immunosorbent assay
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB Ethical Review Board
GCP good clinical practice
HADS Hospital Anxiety and Depression Scale
HIV human immunodeficiency virus
IB Investigator’s Brochure
IBD inflammatory bowel disease
IL interleukin
IL-17A interleukin 17A
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s d ecision to participate. Informed consent is documented by means of a 
written, signed and dated informed consent form .  
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IP investigational product:  A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the authorized 
form, or market ed products used for an unauthorized indication, or marketed products used 
to gain further information about the authorized form.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 50
LY2439821ISR injection site reaction
Legal 
RepresentativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical study.
Lilly Eli Lilly and Company
MedDRA Medical Dictionary for Regulatory Activities
randomize The process of assigning subjects/ patients to an experimental gr oup on a random basis .
PE physical examination
PFS prefilled syringe
PK pharmacokinetic
Ps plaque psoriasis
PsA psoriatic arthritis
RHCA Study I1F-MC -RHCA
RHCK Study I1F-MC -RHCK
RHCS Study I1F-MC -RHCS
RHCT Study I1F -MC -RHCT
RHCU Study I1F -MC -RHCU
SAE serious adverse event
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSARs suspected unexpected serious adverse reactions
TBL total bilirubin level
TE-ADA treatment -emergent antidrug antibody
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment .
t1/2 half-life associated with the terminal rate constant in noncompartmental analysis
tmax time to maximum drug concentration
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 51
LY2439821ULN upper limit of normal
VAS visual analog scale
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 52
LY2439821Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Chloride
Mean cell volume Calcium
Mean cell hemoglobin Phospho rus
Mean cell hemoglobin concentration Glucose random
Leukocytes (WBC) Blood urea nitrogen (BUN)
Platelets Uric acid
Differential WBC absolute counts of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin level (TBL)
Monocytes Direct bilirubin
Eosinophils Alkaline phosphatase (ALP)
Basophils Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Urinalysis Creatinine
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin Other tests
Urobilinogen Ethanol testing a
Blood Urine drug screen a
Nitrite Pregnancy test (females only) b
Microscopy (if dipstick abnormal) FSH (females only, if applicable) c,d
QuantiFERON®-TB Golddor TSTd
Serology
Hepatitis B surface antigen d
Hepatitis B core antibodyd
Hepatitis C antibody d
HIV antibodies d
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
TB= tuberculosis; TST = tuberculin skin test ; WBC = white blood cells.
aUrine drug screen and ethanol (breath test) level will be performed locally at screening and at admission to the 
clinical research unit.  Test may be repeated at additional time points at the discretion of the investigator.   
bSerum pregnancy test to be performed at screening.  Urine pregnancy test to be performed at all other times.  
cFSH test performed for women ≥50 and <55 years of age who have an intact uterus and are not on hormone 
therapy , and have had spontaneous amenorrhea for ≥6 months but <1 year to confirm nonchildbearing potential 
(>40 mIU/mL).
dPerformed at screening only .  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 53
LY2439821Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF) prior to the performance of any  protocol  procedures and prior to the 
administration of invest igational product.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness 
to con tinue his or her participat ion in the study
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative
and retaining a copy  on file
Recruitment
Eli Lilly and Company  (Lilly)or its desi gnee is responsible for the central recruit ment strategy  
for subject s.  Individual invest igators may have addit ional local requi rements or processes.   
Study  specific recruit ment material should be approved by  Lilly.
Ethical Review
The invest igator or appropriate local representativ e must give assurance that the E thical Review 
Board (ERB) was properly const ituted and convened as required by  Internat ional Council for 
Harm onizat ion (ICH) guidelines and other applicable laws and regulat ions.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investigative sites .  Lilly  or its representatives m ust approve the ICF 
before i t is u sed at the invest igative sites .  All  ICFs m ust be compliant wi th the ICH gui deline on 
good clinical pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF 
relevant curri cula vi tae
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 54
LY2439821Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The lead investigator or designee will sign the clinical study  report for thi s study , indicat ing 
agreem ent that, to the best of h is or her knowledge, the report accurately describes the conduct 
and results of the study .
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or h er knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi detraining to i nstruct the invest igators and study  coordinators.  This training
will give instruction on the protocol, the completion of the CRFs, and study  
procedures.
make periodic visit s to the study  site
be available for consult ation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax
review and evaluate case report form ( CRF)data and/or use standard computer edits 
to detect errors in data collect ion
conduct a qualit y review of the database
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 55
LY2439821In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and /or 
regul atory  agencies at any  time.  Invest igators will be given noti ce before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any d ata where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal informat ion collected will be provided in a written 
docum ent to the subject by the s ponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator , or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 56
LY2439821Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Eli Lilly and Com pany or its desi gnee
clinical research physician .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/c onfirmation dependent on regulatory requirements and/or testing availability
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 57
LY2439821Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of ve nipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol I1F-MC -RHCU Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 28 1 28
Clinical laboratory tests a 15.2 4 60.8
Pharmacokinetics 3 15b45
Immunogenicity 10 4 40
Pharmacogenetics 10 1 10
Total 183.8
Total for clinical purposes [rounded up to nearest 10 mL ] 190
aAdditional samples may be drawn if needed for safety purposes.
bIncludes an additional 3 samples, if required.  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 58
LY2439821Appendix 6. Recommended Laboratory  Testing for 
Hypersensitivity  Events
Lab testing should be performed at the time of a Systemic Hypersensit ivity Event. Important 
inform ation about why , when, and what to test for isprovi ded bel ow. The m anagement of the 
adverse event may warrant lab testing beyo nd th at described below and should be performed as 
clinically indicated.
When should labs be obtained?
In the presence of generalized urticaria orif anaphyla xis is suspecte d, after the subject has been 
stabilize d:
obtain a sample within 1 -2 hours of the event ;however, samples may  be obtained as late 
as 12 hours after the event as analytes can remain altered for an extended period of time .  
Record the time at which the sample was co llected.
obtain a fo llow up sam ple at the next regularly  schedul ed visi t or af ter 4 weeks, 
whichever i s later.
Selected tests m ay be obtained in the events of anaphylaxis or generalized urticaria.
Hypersensitivity Testsa
Anti-LY2439821 ant ibodies (immunogenicit y) Tryptaseb
LY2439821 concentration (PK) N-methylhistamine
Drug -specific IgEc
Basophil activation Testc
Com plementsd
Cytokine panele
Abbreviations:  Ig= immunoglobulin; LY2439821 = ixekizumab; PK = pharmacokinetics .
aAssay ed by Lilly -designated laboratory .  These labs are bundled in the Clinical Laboratory Operations 
Hypersensitivity Lab Testing Kit .  
bIf a try ptase sample is obtained more than 2 hours after the event (i.e. ,within 2 to 12 hours), or is not obtained 
because more than 12 hours have lapsed since the event, obtain urine for N-methy lhistamine (NMH) testing. 
Note that f or tryptase serum samples obtained within 2 -12 hours of the event, urine NMH testing is performed in 
addition to tryptase testing. Collect the first void urine following the e vent. Obtain a follow up urine for NMH 
testing at the next regularly scheduled visit or after 4 weeks, whichever is later .
cBasophil activation test will be performed if a drug -specific IgE assay is unavailable .  
dC3a and C5a. 
eIL-6, IL-1β, IL-10 (or any cytokine panel that includes these 3 cytokines) .  
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 59
LY2439821Appendix 7. Protocol A mendment I1F-MC-RHCU( b) 
Summary  Bioequivalence of an A lternate Ixek izumab 
Formulation Compared to the Commercial Formulation 
in Healthy  Subjects
Protocol  I1F-MC-RHCU ,Bioequivalence of an Alternate Ixek izumab F ormulationCompared to 
the Commercial Formulation in Healthy Subjects ,has been amended.  The new protocol is 
indicated by  Amendment ( b) and will be used to conduct the study  in place of any  preceding 
versio n of the protocol.
The o verall changes made to this protocol are as follows:
Modified Ex clusion Cri terion[8]in Section 6.2 to consider em ployees of thi rd-party  
organi zations, in addit ion to emplo yees of Lilly and Covance who areinvolved in the 
study .
Minor edi torial changes an d formatting correcti ons were m ade but are not necessarily 
docum ented in the revisio n below.
Added in verbiage to Section 5 .1for COVID 19 related precautions to be taken by  the 
CRU .
Removed verbiage in Sect ion 10.3.1 on safet y analyses in enro lled patients
I1F-MC-RHCU( b) Clinical Pharmacology Protocol Page 60
LY2439821Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
6.2.Exclusion Criteria
[8]areEli Lilly and Co mpany (Lilly) or Covance emplo yees are employees o f Eli Lilly 
and Co mpany (Lilly), Covance ,or a thi rd-party  organizat ion involved in the study .
5. Study Design
5.1 Overall Design
Parti cipants shoul d follow local guidance and CRU precautions to minimize risk for COVID -19 
infect ion.
10.3. Statis tical Analysis
10.3.1 Safety Analysis
Safety analyses will be conducted for all enro lled subjects, whether or not they  com pleted all  
protocol  requi rements.
Leo Document ID = 9aad3972-e07b-49ac-a25e-2746a4b9c4f9
Approver: 
Approval Date & Time: 28-Sep-2020 20:02:30 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 29-Sep-2020 00:58:37 GMT
Signature meaning: Approved
PPD
PPD